Literature DB >> 25102446

Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: a positive role for peptide dehalogenation.

Emily B Martin1, Stephen J Kennel2, Tina Richey3, Craig Wooliver4, Dustin Osborne5, Angela Williams6, Alan Stuckey7, Jonathan S Wall8.   

Abstract

Dynamic molecular imaging provides bio-kinetic data that is used to characterize novel radiolabeled tracers for the detection of disease. Amyloidosis is a rare protein misfolding disease that can affect many organs. It is characterized by extracellular deposits composed principally of fibrillar proteins and hypersulfated proteoglycans. We have previously described a peptide, p5, which binds preferentially to amyloid deposits in a murine model of reactive (AA) amyloidosis. We have determined the whole body distribution of amyloid by molecular imaging techniques using radioiodinated p5. The loss of radioiodide from imaging probes due to enzymatic reaction has plagued the use of radioiodinated peptides and antibodies. Therefore, we studied iodine-124-labeled p5 by using dynamic PET imaging of both amyloid-laden and healthy mice to assess the rates of amyloid binding, the relevance of dehalogenation and the fate of the radiolabeled peptide. Rates of blood pool clearance, tissue accumulation and dehalogenation of the peptide were estimated from the images. Comparisons of these properties between the amyloid-laden and healthy mice provided kinetic profiles whose differences may prove to be indicative of the disease state. Additionally, we performed longitudinal SPECT/CT imaging with iodine-125-labeled p5 up to 72h post injection to determine the stability of the radioiodinated peptide when bound to the extracellular amyloid. Our data show that amyloid-associated peptide, in contrast to the unbound peptide, is resistant to dehalogenation resulting in enhanced amyloid-specific imaging. These data further support the utility of this peptide for detecting amyloidosis and monitoring potential therapeutic strategies in patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amyloid imaging; Dehalogenation; Dynamic PET imaging; Peptide radiotracer; SPECT

Mesh:

Substances:

Year:  2014        PMID: 25102446      PMCID: PMC4169731          DOI: 10.1016/j.peptides.2014.07.024

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  38 in total

1.  Binding of a de novo designed peptide to specific glycosaminoglycans.

Authors:  G Jayaraman; C W Wu; Y J Liu; K Y Chien; J C Fang; P C Lyu
Journal:  FEBS Lett       Date:  2000-09-29       Impact factor: 4.124

2.  Localization of type I iodothyronine 5'-deiodinase to the basolateral plasma membrane in renal cortical epithelial cells.

Authors:  J L Leonard; D M Ekenbarger; S J Frank; A P Farwell; J Koehrle
Journal:  J Biol Chem       Date:  1991-06-15       Impact factor: 5.157

Review 3.  Imaging amyloidosis with radiolabelled SAP.

Authors:  P N Hawkins; M B Pepys
Journal:  Eur J Nucl Med       Date:  1995-07

Review 4.  Diagnosis and monitoring of amyloidosis.

Authors:  P N Hawkins
Journal:  Baillieres Clin Rheumatol       Date:  1994-08

Review 5.  Imaging techniques in the diagnosis of dialysis-related amyloidosis.

Authors:  M Ketteler; K M Koch; J Floege
Journal:  Semin Dial       Date:  2001 Mar-Apr       Impact factor: 3.455

6.  Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate.

Authors:  P K Garg; K L Alston; P C Welsh; M R Zalutsky
Journal:  Bioconjug Chem       Date:  1996 Mar-Apr       Impact factor: 4.774

7.  Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component.

Authors:  S R Nelson; P N Hawkins; S Richardson; J P Lavender; D Sethi; P E Gower; C W Pugh; C G Winearls; D O Oliver; M B Pepys
Journal:  Lancet       Date:  1991-08-10       Impact factor: 79.321

8.  Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.

Authors:  M B Pepys; T W Rademacher; S Amatayakul-Chantler; P Williams; G E Noble; W L Hutchinson; P N Hawkins; S R Nelson; J R Gallimore; J Herbert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

9.  Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils.

Authors:  S R Nelson; M Lyon; J T Gallagher; E A Johnson; M B Pepys
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

10.  Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation.

Authors:  A Rydh; O Suhr; S O Hietala; K R Ahlström; M B Pepys; P N Hawkins
Journal:  Eur J Nucl Med       Date:  1998-07
View more
  12 in total

1.  Mechanistic insights into the pH-dependent membrane peptide ATRAM.

Authors:  Vanessa P Nguyen; Loganathan Palanikumar; Stephen J Kennel; Daiane S Alves; Yujie Ye; Jonathan S Wall; Mazin Magzoub; Francisco N Barrera
Journal:  J Control Release       Date:  2019-02-11       Impact factor: 9.776

2.  Specific Amyloid Binding of Polybasic Peptides In Vivo Is Retained by β-Sheet Conformers but Lost in the Disrupted Coil and All D-Amino Acid Variants.

Authors:  Jonathan S Wall; Angela Williams; Tina Richey; Alan Stuckey; Craig Wooliver; J Christopher Scott; Robert Donnell; Emily B Martin; Stephen J Kennel
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

Review 3.  Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection.

Authors:  Omid Tavassoly; Farinaz Safavi; Iman Tavassoly
Journal:  Mol Pharmacol       Date:  2020-09-10       Impact factor: 4.436

4.  Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.

Authors:  Libin Zhang; Rui Zhang; Jiyuan Yang; Jiawei Wang; Jindřich Kopeček
Journal:  J Control Release       Date:  2016-06-04       Impact factor: 9.776

5.  The pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in mice.

Authors:  Stephen J Kennel; Angela Williams; Alan Stuckey; Tina Richey; Craig Wooliver; Walter Chazin; David A Stern; Emily B Martin; Jonathan S Wall
Journal:  Amyloid       Date:  2015-12-24       Impact factor: 7.141

6.  Discrete binding patterns of two heparin-reactive proteins, basic fibroblast growth factor and peptide p5R, in amyloid-laden and healthy mice.

Authors:  Emily B Martin; Robert Donnell; Tina Richey; Alan Stuckey; Stephen J Kennel; Jonathan S Wall
Journal:  Biochem Biophys Res Commun       Date:  2021-03-19       Impact factor: 3.575

7.  Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis.

Authors:  Jonathan S Wall; Emily B Martin; Tina Richey; Alan C Stuckey; Sallie Macy; Craig Wooliver; Angela Williams; James S Foster; Penney McWilliams-Koeppen; Ed Uberbacher; Xiaolin Cheng; Stephen J Kennel
Journal:  Molecules       Date:  2015-04-27       Impact factor: 4.411

8.  A Peptide-Fc Opsonin with Pan-Amyloid Reactivity.

Authors:  James S Foster; Angela D Williams; Sallie Macy; Tina Richey; Alan Stuckey; Daniel Craig Wooliver; Richa Koul-Tiwari; Emily B Martin; Stephen J Kennel; Jonathan S Wall
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

9.  Evaluation of the effect of D-amino acid incorporation into amyloid-reactive peptides.

Authors:  Emily B Martin; Angela Williams; Tina Richey; Craig Wooliver; Alan Stuckey; James S Foster; Stephen J Kennel; Jonathan S Wall
Journal:  J Transl Med       Date:  2017-12-11       Impact factor: 5.531

10.  Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis.

Authors:  Emily B Martin; Angela Williams; Tina Richey; Alan Stuckey; R Eric Heidel; Stephen J Kennel; Jonathan S Wall
Journal:  Sci Rep       Date:  2016-03-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.